Associate Professor, University of Michigan Medical School
Oncology
Dr. Patrick J. Hu, MD
|
|
Give Review
Patrick practices Oncology. He graduated from NYU School of Medicine. He received awards:"CMS Meaningful Use Stage 1 Certification" and "Elected Member". Doctor Patrick J. Hu, MD is a published physician. He has 32 papers published. The most current publication "Polyarteritis nodosa of the pericardium: antemortem diagnosis in a pericardiectomy specimen." He accepts all Medicare patients.
Publications
- Chromoanasynthetic Genomic Rearrangement Identified in a N-ethyl-N-nitrosourea (ENU) Mutagenesis Screen in Caenorhabditis elegans.
- Longevity Genes Revealed by Integrative Analysis of Isoform-Specific daf-16/FoxO Mutants of Caenorhabditis elegans.
- Whole genome sequencing and the transformation of C. elegans forward genetics.
- Comparative metabolomics reveals endogenous ligands of DAF-12, a nuclear hormone receptor, regulating C. elegans development and lifespan.
- TATN-1 Mutations Reveal a Novel Role for Tyrosine as a Metabolic Signal That Influences Developmental Decisions and Longevity in Caenorhabditis elegans.
- Effects of Caenorhabditis elegans sgk-1 mutations on lifespan, stress resistance, and DAF-16/FoxO regulation.
- Unexpected Role for Dosage Compensation in the Control of Dauer Arrest, Insulin-Like Signaling, and FoxO Transcription Factor Activity in Caenorhabditis elegans.
- The Influence of Steroid Hormone Signaling on Life Span Controlby Caenorhabditis elegans Insulin-Like Signaling.
- Ovarian steroid cell tumor with biallelic adenomatous polyposis coli inactivation in a patient with familial adenomatous polyposis.
- EAK proteins: novel conserved regulators of C. elegans lifespan.
- EAK-7 controls development and life span by regulating nuclear DAF-16/FoxO activity.
- Functional divergence of dafachronic acid pathways in the control of C. elegans development and lifespan.
- DANSing with Caenorhabditis elegans.
- Caenorhabditis elegans EAK-3 inhibits dauer arrest via nonautonomous regulation of nuclear DAF-16/FoxO activity.
- Dauer.
- Two membrane-associated tyrosine phosphatase homologs potentiate C. elegans AKT-1/PKB signaling.
- Systematic interactome mapping and genetic perturbation Analysis of a C. elegans TGF-beta signaling network.
- Polyarteritis nodosa of the pericardium: antemortem diagnosis in a pericardiectomy specimen.
- Phosphatidylinositol 3-kinase mediates epidermal growth factor-induced activation of the c-Jun N-terminal kinase signaling pathway.
- Point mutation in the fibroblast growth factor receptor eliminates phosphatidylinositol hydrolysis without affecting neuronal differentiation of PC12 Cells.
- Direct association of p110 beta phosphatidylinositol 3-kinase with p85 is mediated by an N-terminal fragment of p110 beta.
- Cloning of a novel, ubiquitously expressed human phosphatidylinositol 3-kinase and identification of its binding site on p85.
- Vav: a potential link between tyrosine kinases and ras-like GTPases in hematopoietic Cell signaling.
- Phosphatidylinositol 3-kinase p85 SH2 domain specificity defined by direct phosphopeptide/SH2 domain binding.
- SH2 domains exhibit high-affinity binding to tyrosine-phosphorylated peptides yet also exhibit rapid dissociation and exchange.
- Specific phosphopeptide binding regulates a conformational change in the PI 3-kinase SH2 domain associated with enzyme activation.
- The SH2 and SH3 domain-containing Nck protein is oncogenic and a common target for phosphorylation by different surface receptors.
- IRS-1 activates phosphatidylinositol 3'-kinase by associating with src homology 2 domains of p85.
- Phosphatidylinositol 3'-kinase is activated by association with IRS-1 during insulin stimulation.
- Interaction of phosphatidylinositol 3-kinase-associated p85 with epidermal growth factor and platelet-derived growth factor receptors.
- Tyrosine phosphorylation of vav proto-oncogene proDuct containing SH2 domain and transcription factor motifs.
Schools
New York University
Conditions Treated
- Anal and Rectal Cancer
- Anemia
- Bile Duct Cancer
- Bladder Cancer
- View All
Doctors Specialties
- Medical Oncology
- Oncology
Accepted Insurances
Awards
- CMS Meaningful Use Stage 1 Certification
- Elected Member
Education
-
Massachusetts General Hospital -
Johns Hopkins University -
NYU School of Medicine
Hospital
-
University of Michigan Hospitals and Health Centers
Drug Facts
| NPI NUMBER | 1124107032 | |
| NPPES Provider LastName | HU | |
| NPPES Provider FirstName | PATRICK | |
| NPPES Provider ZIPCode | 481095912 | |
| NPPES Provider State | MI | |
| Specialty Description | Medical Oncology | |
| Total Claim Count | 265.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1124107032 |
| Last Name Of The Provider | HU |
| First Name Of The Provider | PATRICK |
| View All |
Similar Doctors
|
|
Dr. Rashmi Chugh, MD
 This Doctor is OpenDoctor Recommended.
|
|
Dr. Todd M. Morgan, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Jeffrey B. Smerage, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Nathalie A. Brophy, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Kathleen A. Cooney, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Douglas W. Blayney, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Monika L. Burness, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Moshe Talpaz, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Catherine H. Van Poznak, MD |
|
|
Dr. Scott M. Schuetze, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Stephen B. Gruber, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|